GenSight Biologics will participate to the 2019 ARVO annual meeting, at the Vancouver Convention Centre in Vancouver, British Columbia.

The 72-week results from the REVERSE and RESCUE Phase III clinical trials of GS010 will be presented by Dr. Patrick Yu-Wai-Man, MD, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, and MRC Mitochondrial Biology Unit, University of Cambridge, United Kingdom; NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom. Dr. Yu-Wai-Man is also the International Coordinating Investigator of REVERSE.

  • Oral presentation title:  “rAAV2/2-ND4 for the Treatment of Leber Hereditary Optic Neuropathy (LHON): 72-Week Data from the REVERSE Phase III Clinical Trial
  • Scientific Section: Eye Movements, Strabismus, Amblyopia, Neuro-Ophthalmology
  • Location: West 221/222
  • Session: Optic Neuropathy, Paper Session
  • Wednesday, May 1, 10:30 am – 10:45 am PDT